Climb Bio, Inc. (CLYM) vs CorMedix Inc. (CRMD)
A side-by-side comparison of Climb Bio, Inc. and CorMedix Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLYM
Climb Bio, Inc.
$10.68HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
CRMD
CorMedix Inc.
$7.28HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CLYM vs CRMD
growth of $100 · dividends reinvested · last 2yCLYM +41.1% (+18.8%/yr)CRMD +24.3% (+11.5%/yr)CLYM compounded faster over this window
CLYM CRMD
CLYM vs CRMD: by the numbers
- •CLYM is the larger company ($612M vs $571M market cap).
- •CRMD is profitable (40.49% net margin) while CLYM runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | CLYM | CRMD |
|---|---|---|
| P/E ratio | N/A | 3.42 |
| Forward P/E | N/A | 14.71 |
| P/S ratio | N/A | 1.24 |
| P/B ratio | 2.55 | 1.24 |
| EV / EBITDA | N/A | 1.82 |
| FCF yield | N/A | 43.82% |
Profitability
| Metric | CLYM | CRMD |
|---|---|---|
| Gross margin | 0.00% | 82.78% |
| Operating margin | 0.00% | 46.95% |
| Net margin | 0.00% | 40.49% |
| ROE | -24.06% | 40.62% |
| ROIC | -26.94% | 27.87% |
Growth (annualized)
| Metric | CLYM | CRMD |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 352.03% |
| Total return CAGR (5Y) | N/A | 9.70% |
Frequently asked
- Is CLYM or CRMD more profitable?
- CRMD runs the higher net margin — CLYM at 0.00% versus CRMD at 40.49%.
Go deeper
Dig into the metrics
CorMedix P/E ratioClimb Bio ROECorMedix ROEClimb Bio operating marginCorMedix operating marginClimb Bio revenue growthCorMedix revenue growthClimb Bio free cash flowCorMedix free cash flow
Climb Bio & CorMedix appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.